Phase I trial of intratumoral therapy using HF10, an oncolytic HSV-1, demonstrates safety in HSV+/HSV- patients with refractory and superficial cancers.
Robert L. Ferris(University of Pittsburgh), Yukihiro Nishiyama(Nagoya University), Maki Tanaka(Takara (Japan)), John T. Vetto(Oregon Health & Science University), Richard S. Ungerleider(Unknown), John Nemunaitis(Gradalis (United States)), Neil D. Gross(The University of Texas MD Anderson Cancer Center), James Ohr(University of Pittsburgh), Cindi Bedell(Mary Crowley Cancer Research Center), Athanassios Argiris(The University of Texas at San Antonio Health Science Center), Neil Senzer(Mary Crowley Cancer Research Center), Robert Hans Ingemar Andtbacka(University of Utah)
Cited by 30
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.
|Journal of Clinical Oncology|1996|914
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
|Oral Oncology|2018|802
Phase III Trial of Gemcitabine Plus Cisplatin Versus Cisplatin Alone in Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2000|719